The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different
experimental models of chronic liver injury. We aimed to determine the safety and efficacy of
moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo
risk score, and health-related quality of life in patients with primary biliary cirrhosis
(PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).